OOIR: Observatory of International Research

Papers

(The H4-Index of Lancet HIV is 42. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Argentina updates HIV laws	292
Evidence supports use of on-demand PrEP for HIV prevention	151
Transplant donation without discrimination	139
How do we prevent anal cancer in people living with HIV?	138
Safety, tolerability, and pharmacokinetics of an annual tenofovir alafenamide silicone subdermal implant in South African women: a two-part, randomised, placebo-controlled, double-blind, first-in-huma	111
Rapid access to antiretroviral therapy, receipt of naltrexone, and strengths-based case management versus standard of care for HIV viral load suppression in people with HIV who inject drugs in Russia	110
Correction to Lancet HIV 2022; 9: e791–800	109
How much could long-acting PrEP cost in South Africa?	109
The Australian AIDS crisis through the eyes of volunteers	101
HIV and COVID-19: juxtaposition of two pandemics	97
Optimising anal cancer screening through risk stratification	91
A moment of reckoning	86
Lenacapavir: an attractive option, but proceed with caution	83
Free HIV self-test for identification and linkage to care of previously undetected HIV infection in men who have sex with men in England and Wales (SELPHI): an open-label, internet-based, randomised c	82
Standard-dose versus double-dose dolutegravir in HIV-associated tuberculosis in South Africa (RADIANT-TB): a phase 2, non-comparative, randomised controlled trial	78
Lung cancer in people living with HIV	77
Controversial chronicler of LGBTQ rights	74
Risk estimation in HIV reveals our usual blind spots	74
Scaling up access to HIV pre-exposure prophylaxis (PrEP): should nurses do the job?	66
Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority ODYSSEY trial	64
Are we ready for long-acting HIV treatment for adolescents?	59
Safety and pharmacokinetics of dolutegravir dispersible tablets and oral films in term neonates exposed to HIV in South Africa (PETITE-DTG study): an open-label, randomised, phase 1/2 trial	57
Unheard testimony	56
Steps toward quick and equitable roll-out of lenacapavir	56
Game-changing study of second-line HIV treatment	55

Gains and gaps: addressing HIV in diverse sex worker groups	53
All roads lead to Westminster: the infected blood scandal	52
Redefining care: injectable HIV treatment for adolescents	51
Fate of people with HIV in jeopardy in Ukraine	51
Making America unhealthy again	50
The contribution of intimate partner violence to vertical HIV transmission: a modelling analysis of 46 African countries	49
Suicide prevention research is crucial to achieving health equity for people with HIV	48
Equitable access to long-acting PrEP on the way?	48
Recent gay Black history in the UK	46
Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E–4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial	45
WHO recommends lenacapavir for HIV prevention	45
Sex as a biological variable in HIV-1 and schistosome co-infection	45
Reducing HIV transmission in British Columbia, Canada	45
A public health approach to drug use crucial to ending AIDS	44
Stigma reduction is key to improving the HIV care continuum	42
Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis	42
More evidence for worse COVID-19 outcomes in people with HIV	42
HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study	42
Integration of sexual health and HIV services	42